465
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Research

DNMT3A R882 mutation is associated with elevated expression of MAFB and M4/M5 immunophenotype of acute myeloid leukemia blasts

, , &
Pages 2914-2922 | Received 10 Oct 2014, Accepted 31 Jan 2015, Published online: 06 Jul 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Juan Ma, Jennifer Dunlap, Aleksandra Paliga, Elie Traer, Richard Press, Lisong Shen & Guang Fan. (2018) DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. Leukemia & Lymphoma 59:8, pages 1938-1948.
Read now

Articles from other publishers (9)

Yujiao Zhang, Quan Wu, Baoyi Yuan, Yun Huang, Ling Jiang, Fang Liu, Ping Yan, Yongshuai Jiang, Jieyu Ye & Xuejie Jiang. (2023) Influence on therapeutic outcome of platelet count at diagnosis in patients with de novo non-APL acute myeloid leukemia. BMC Cancer 23:1.
Crossref
Li-Xue Yang, Cheng-Tao Zhang, Meng-Ying Yang, Xue-Hong Zhang, Hong-Chen Liu, Chen-Hui Luo, Yue Jiang, Zhang-Man Wang, Zhong-Yin Yang, Zhao-Peng Shi, Yi-Ci Yang, Ruo-Qu Wei, Li Zhou, Jun Mi, Ai-Wu Zhou, Zhi-Rong Yao, Li Xia, Jin-Song Yan & Ying Lu. (2023) C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse. Blood 141:7, pages 766-786.
Crossref
Xuan Chu, Liang Zhong, Wenran Dan, Xiao Wang, Zhonghui Zhang, Zhenyan Liu, Yang Lu, Xin Shao, Ziwei Zhou, Shuyu Chen & Beizhong Liu. (2022) DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway. Cell Communication and Signaling 20:1.
Crossref
Yimei Que, Huimin Li, Liman Lin, Xiaojian Zhu, Min Xiao, Ying Wang, Li Zhu & Dengju Li. (2021) Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation. Frontiers in Immunology 12.
Crossref
Yanyan Chen, Tao Wang, Mengxi Huang, Qin Liu, Chao Hu, Bin Wang, Dong Han, Cheng Chen, Junliang Zhang, Zhiping Li, Chao Liu, Wenbin Lei, Yue Chang, Meijuan Wu, Dan Xiang, Yitian Chen, Rui Wang, Weiqian Huang, Zengjie Lei & Xiaoyuan Chu. (2020) MAFB Promotes Cancer Stemness and Tumorigenesis in Osteosarcoma through a Sox9-Mediated Positive Feedback Loop. Cancer Research 80:12, pages 2472-2483.
Crossref
Li Yang, Ke'Feng Shen, Mei'Lan Zhang, Wei Zhang, Hao'Dong Cai, Li'Man Lin, Xiao'Lu Long, Shu'Gang Xing, Yang Tang, Jie Xiong, Jia'Chen Wang, Deng'Ju Li, Jian'Feng Zhou & Min Xiao. (2019) Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations. Frontiers in Oncology 9.
Crossref
Kevin Dzobo. (2019) Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment “jigsaw puzzle”. OMICS: A Journal of Integrative Biology 23:2, pages 70-85.
Crossref
Vanessa Szablewski, Caroline Bret, Alboukadel Kassambara, Julie Devin, Guillaume Cartron, Valérie Costes-Martineau & Jérôme Moreaux. (2018) An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. Oncotarget 9:27, pages 19079-19099.
Crossref
Lin-Sen Yang, Xiao-Jian Zhang, Yin-Yin Xie, Xiao-Jian Sun, Ren Zhao & Qiu-Hua Huang. (2016) SUMOylated MAFB promotes colorectal cancer tumorigenesis. Oncotarget 7:50, pages 83488-83501.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.